{
    "clinical_study": {
        "@rank": "124372", 
        "acronym": "LV RESTORE-SA", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The study is designed to demonstrate the safety, feasibility and potential efficacy of using\n      the GDS Accucinch System to reduce functional mitral regurgitation."
        }, 
        "brief_title": "Percutaneous Left Ventricular Reshaping to Reduce Functional Mitral Regurgitation and Improve LV Function", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Functional Mitral Regurgitation", 
        "condition_browse": {
            "mesh_term": "Mitral Valve Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >18 years\n\n          -  Subjects with clinically significant mitral regurgitation (MR 2+ and above)\n\n          -  Ejection Fraction \u2265 25%\n\n          -  Stable cardiac medical regimen for heart failure for at least 1 month\n\n          -  Stable NYHA Classification for at least 1 month\n\n          -  Subject is eligible for cardiac surgery\n\n          -  The subject has been informed of the nature of the study, agrees to its provisions,\n             and has provided written informed consent\n\n        Exclusion Criteria:\n\n          -  Myocardial infarction within 90 days of the intended treatment with the device\n\n          -  Prior surgical, transcatheter, or percutaneous mitral valve intervention\n\n          -  Any intervention for coronary artery disease (CAD) within the last 30 days prior to\n             treatment, or unrevascularized multivessel coronary disease\n\n          -  Hemodynamic instability or the need for emergent surgery\n\n          -  Non-ambulatory NYHA Class IV symptoms of heart failure or subjects requiring IV\n             inotropic support\n\n          -  Subjects in whom sufficient quality of echocardiography (TTE and TEE) cannot be\n             obtained\n\n          -  Echocardiography evidence of primary mitral valve disease causing MR or MS,\n\n          -  Evidence of mitral valve stenosis with an estimated valve area less than 3.0 cm2\n\n          -  Mitral valve prosthesis or pathology that would prevent adequate function of the GDS\n             Accucinch System\n\n          -  Estimated GFR of <30ml/min/1.73m2\n\n          -  Greater than mild mitral annular calcification observed by fluoroscopy\n\n          -  Presence of aortic valve prosthesis\n\n          -  Moderate to severe aortic valve stenosis or calcification observed by\n             echocardiography or fluoroscopy\n\n          -  Severe aortic arch calcification or mobile aortic atheroma observed by\n             echocardiography or fluoroscopy\n\n          -  Active bacterial endocarditis\n\n          -  History of bleeding diathesis or coagulopathy\n\n          -  History of stroke within the prior 6 months\n\n          -  Subjects in whom anticoagulation is contraindicated\n\n          -  Any clinical evidence that the investigator feels would place the subject at\n             increased risk with the placement of the device.\n\n          -  Concurrent medical condition with a life expectancy of less than 12 months\n\n          -  Currently participating in an investigational study\n\n          -  Co-morbid conditions that place the subject at an unacceptable surgical risk (e.g.\n             severe chronic obstructive pulmonary disease, hepatic failure, immunological\n             abnormalities, and hematological abnormalities)\n\n          -  Subjects with indication for concomitant surgery such as coronary artery bypass graft\n             (CABG), aortic valve reconstruction or replacement, tricuspid repair or replacement,\n             left ventricular remodeling surgery and congenital repair\n\n          -  Any cardiac resynchronization therapy within the last 3 months prior to treatment\n\n          -  Subjects on high dose steroids or immunosuppressant therapy\n\n          -  Female subjects who are pregnant, of child bearing potential or lactating\n\n          -  Subjects who are unable or unwilling to comply with the follow-up schedule and\n             requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01899573", 
            "org_study_id": "3566"
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "description": "Percutaneous intervention for the treatment of functional mitral regurgitation", 
            "intervention_name": "GDS Accucinch\u00ae", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Heart failure", 
            "mitral regurgitation", 
            "mitral valve"
        ], 
        "lastchanged_date": "September 11, 2013", 
        "number_of_arms": "1", 
        "official_title": "A Study of Percutaneous Left Ventricular Reshaping of Mitral Apparatus to Reduce Functional Mitral Regurgitation and Improve LV Function Using the Accucinch\u00ae System", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Colombia: Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Major adverse cardiac and cardiovascular events", 
            "safety_issue": "Yes", 
            "time_frame": "30 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01899573"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Guided Delivery Systems Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guided Delivery Systems Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}